AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 152 filers reported holding AKERO THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 1.85 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $64,828,892 | +1053.2% | 1,281,710 | +964.5% | 0.03% | +1300.0% |
| Q2 2023 | $5,621,709 | +98.9% | 120,405 | +63.0% | 0.00% | +100.0% |
| Q1 2023 | $2,827,031 | +49.2% | 73,890 | +113.7% | 0.00% | 0.0% |
| Q4 2022 | $1,894,984 | +126.9% | 34,580 | +41.0% | 0.00% | – |
| Q3 2022 | $835,000 | +313.4% | 24,528 | +14.6% | 0.00% | – |
| Q2 2022 | $202,000 | -11.0% | 21,400 | +33.8% | 0.00% | – |
| Q1 2022 | $227,000 | -32.8% | 16,000 | 0.0% | 0.00% | – |
| Q4 2021 | $338,000 | -5.6% | 16,000 | 0.0% | 0.00% | – |
| Q3 2021 | $358,000 | -23.7% | 16,000 | -15.3% | 0.00% | – |
| Q2 2021 | $469,000 | +10.1% | 18,900 | +28.6% | 0.00% | – |
| Q1 2021 | $426,000 | -3.0% | 14,700 | -13.5% | 0.00% | – |
| Q4 2020 | $439,000 | -23.8% | 17,000 | -9.1% | 0.00% | – |
| Q3 2020 | $576,000 | +4.5% | 18,700 | -15.4% | 0.00% | – |
| Q2 2020 | $551,000 | +83.1% | 22,100 | +55.6% | 0.00% | – |
| Q1 2020 | $301,000 | – | 14,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
| Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
| Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
| COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
| Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
| Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
| Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
| Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |